灵北公司再赴进博：来自丹麦神经科学专注创新者的“中国承诺”

Core Viewpoint - The eighth China International Import Expo (CIIE) showcased significant advancements in neuroscience, particularly highlighting the global Phase III clinical study of the innovative therapy bexicaserin for developmental epileptic encephalopathy (DEE) by the pharmaceutical company Lingbei, emphasizing the importance of the expo as a platform for global collaboration in healthcare [1][2][4]. Group 1: Company Developments - Lingbei has established itself as a key player in the treatment of rare neurological diseases in China, having launched six products since its establishment in 2007 and serving 74 million patients [2][8]. - The company is initiating three international multicenter Phase III clinical studies for bexicaserin in collaboration with several leading Chinese medical institutions, aiming to address the urgent need for effective treatments for DEE [3][4]. - Bexicaserin has received breakthrough therapy designation from both the FDA and China's National Medical Products Administration, highlighting its potential to significantly improve treatment options for DEE patients [4][6]. Group 2: Product Innovations - The new drug bexicaserin is a novel oral 5-HT2C receptor agonist designed to reduce drug-resistant seizures in DEE patients, showing promising efficacy and safety in preliminary clinical trials [3][4]. - Lingbei's migraine treatment, eptinezumab, has demonstrated significant efficacy in reducing the frequency of migraine attacks in Asian populations, addressing the unmet need for preventive treatment among the 130 million migraine sufferers in China [5][6]. Group 3: Strategic Initiatives - Lingbei invests 20% of its annual revenue (approximately 4 billion Danish kroner) into research and development, focusing 90% of its pipeline on rare neurological diseases and specialized neurological fields [7]. - The company has been actively involved in enhancing public awareness of neurological diseases and patient education, collaborating with various stakeholders to build a comprehensive brain health ecosystem in China [8][9]. - Lingbei aims to contribute to the "Healthy China 2030" initiative by developing transformative treatment solutions for neurological diseases through sustained R&D investment and local partnerships [9].